While olaparib did not meet the pre-specified response-based threshold to proceed with a Phase 3 trial in IDH-mutant glioma patients, a subset of patients demonstrated prolonged stable disease, suggesting that olaparib may still be clinically useful as a form of maintenance therapy for a subset of GBM patients [144]. Here, IDH1 is linked to glioma.